Anaplastic Thyroid Cancer - Pipeline Review, H2 2012

Anaplastic Thyroid Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2012', provides an overview of the Anaplastic Thyroid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer. 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anaplastic Thyroid Cancer.
- A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Anaplastic Thyroid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Anaplastic Thyroid Cancer Therapeutic Products under Development, Key Players in Anaplastic Thyroid Cancer Therapeutics, Anaplastic Thyroid Cancer Pipeline Overview, Anaplastic Thyroid Cancer Pipeline, Anaplastic Thyroid Cancer Pipeline Assessment SHOW LESS READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Anaplastic Thyroid Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Anaplastic Thyroid Cancer 7
Anaplastic Thyroid Cancer Therapeutics under Development by Companies 9
Anaplastic Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Anaplastic Thyroid Cancer Therapeutics – Products under Development by Companies 14
Anaplastic Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Anaplastic Thyroid Cancer Therapeutics Development 16
Daiichi Sankyo Company, Ltd 16
Plexxikon Inc. 17
Exelixis, Inc. 18
OXiGENE, Inc. 19
Anaplastic Thyroid Cancer – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BAY 43-9006 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
PLX 3397 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Hydroxyurea + Fluorouracil + Paclitaxel + G-CSF + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Zybrestat - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cisplatin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Paclitaxel + Pazopanib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Sutent - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CS-7017 + Paclitaxel - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Alimta + Paclitaxel - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Anaplastic Thyroid Cancer Therapeutics – Drug Profile Updates 40
Anaplastic Thyroid Cancer Therapeutics – Discontinued Products 44
Anaplastic Thyroid Cancer Therapeutics - Dormant Products 45
Anaplastic Thyroid Cancer – Product Development Milestones 46
Featured News & Press Releases 46
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products Under Development for Anaplastic Thyroid Cancer, H2 2012 7
Products under Development for Anaplastic Thyroid Cancer – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Daiichi Sankyo Company, Ltd, H2 2012 16
Plexxikon Inc., H2 2012 17
Exelixis, Inc., H2 2012 18
OXiGENE, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Anaplastic Thyroid Cancer Therapeutics – Drug Profile Updates 40
Anaplastic Thyroid Cancer Therapeutics – Discontinued Products 44
Anaplastic Thyroid Cancer Therapeutics – Dormant Products 45

List of Figures
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2012 7
Products under Development for Anaplastic Thyroid Cancer – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25